OTIC Otonomy Inc.

2.52
-0.06  -2%
Previous Close 2.58
Open 2.58
Price To Book 1.53
Market Cap 77,490,106
Shares 30,750,042
Volume 162,542
Short Ratio
Av. Daily Volume 77,287
Stock charts supplied by TradingView

NewsSee all news

  1. Otonomy to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D.,

  2. Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière's diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common

  3. Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update

    SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial

  4. AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

    GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of

  5. Otonomy to Present at the Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data due 2H 2020.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 data due 2Q 2020.
OTO-313
Tinnitus
Additional Phase 3 trial data due 3Q 2020.
OTIVIDEX
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. Otonomy to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D.,

  2. Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière's diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common

  3. Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update

    SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial

  4. AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

    GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of

  5. Otonomy to Present at the Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber,

  6. Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

    SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase